These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 21102634)

  • 1. Shared and separate functions of polo-like kinases and aurora kinases in cancer.
    Lens SM; Voest EE; Medema RH
    Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
    Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
    Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?
    Archambault V; Carmena M
    Cell Cycle; 2012 Apr; 11(8):1490-5. PubMed ID: 22433949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
    Christoph DC; Schuler M
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo and Aurora kinases: lessons derived from chemical biology.
    Taylor S; Peters JM
    Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
    Warner SL; Gray PJ; Von Hoff DD
    Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.
    Warner SL; Stephens BJ; Von Hoff DD
    Curr Oncol Rep; 2008 Mar; 10(2):122-9. PubMed ID: 18377825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis.
    Li JJ; Li SA
    Pharmacol Ther; 2006 Sep; 111(3):974-84. PubMed ID: 16603252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.
    Luo J; Liu X
    Protein Cell; 2012 Mar; 3(3):182-97. PubMed ID: 22447658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of myosin II-interacting guanine nucleotide exchange factor (MyoGEF) at threonine 544 by aurora B kinase promotes the binding of polo-like kinase 1 to MyoGEF.
    Wu D; Asiedu M; Matsumura F; Wei Q
    J Biol Chem; 2014 Mar; 289(10):7142-7150. PubMed ID: 24482237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora B: a new prognostic marker and therapeutic target in cancer.
    Portella G; Passaro C; Chieffi P
    Curr Med Chem; 2011; 18(4):482-96. PubMed ID: 21143115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The serine/threonine kinases that control cell cycle progression as therapeutic targets].
    Diallo A; Prigent C
    Bull Cancer; 2011 Nov; 98(11):1335-45. PubMed ID: 22020767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery.
    Macůrek L; Lindqvist A; Lim D; Lampson MA; Klompmaker R; Freire R; Clouin C; Taylor SS; Yaffe MB; Medema RH
    Nature; 2008 Sep; 455(7209):119-23. PubMed ID: 18615013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting in and out of mitosis with Polo-like kinase-1.
    van Vugt MA; Medema RH
    Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora-A and hBora join the game of Polo.
    Macurek L; Lindqvist A; Medema RH
    Cancer Res; 2009 Jun; 69(11):4555-8. PubMed ID: 19487276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora-B kinase inhibitors for cancer chemotherapy.
    Yeung SC; Gully C; Lee MH
    Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.
    Jadhav M; Sankhe K; Bhandare RR; Edis Z; Bloukh SH; Khan TA
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.
    Pérez Fidalgo JA; Roda D; Roselló S; Rodríguez-Braun E; Cervantes A
    Clin Transl Oncol; 2009 Dec; 11(12):787-98. PubMed ID: 20045785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.